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ABSTRACT (English Version) 
Thrombosis is a pathologic condition that occurs when the body forms 
arterial or venous blood clots that are excessively large and obstruct blood flow. 
Heart attack, stroke or pulmonary embolism are examples of conditions when 
develop in blood vessels which may contribute to various symptoms and 
complications. Therefore the search for an effective agent that can secure full 
antithrombotic benefits while minimizing the antihaemostatic outcome should be 
pursued. In this study, in order to assess the effect of Ganoderma lucidum in 
inhibition of platelet aggregation, two types of extract were prepared from crude 
powder of commercially available products of Ganoderma lucidum. Both the two 
types of extracts were tested for their activities on blood cells in vitro. The effects of 
this mushroom were tested based on the changes in hematological parameters 
following the treatment with different doses of water and ethanol extract 
Ganoderma Jucidum using hematology analyzer (Abbott Celldyn 4000). The test 
duration for the observation was set for 2 hours and the observation were made 
every 30 minutes intervals. From this study, the results showed that there were no 
significant difference of effect between different doses of water and ethanol 
extracts on MPV. However, there were significant differences of the effect of 
extracts of Ganoderma lucidum in different concentration on MPV at different time 
intervals. Antiplatelet aggregation activities by indirect evaluation of changes in 
blood cells parameters in vitro following the treatment with Ganoderma Jucidum 
extract may not be fully explored or elucidated by the in vitro study. However, the 
XII 
results from this preliminary study will assist in establishing the direction of an in 
vivo study, which will be followed. In order to look at the activities of platelet and 
the effects on other hematological parameters in vivo, a long-term prospective 
study should be explored to prove the potential use of Ganoderma lucidum 
mushroom as a prophylactic agent for prevents arterial thrombosis. 
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ABSTRAK (Malay Version) 
Penyakit yang berhubung dengan trombosis seperti serangan jantung, 
renjatan, emboli pulmonari dan lain-lain merupakan penyebab maut yang paling 
kerap di negara maju. Trombosis adalah satu keadaan patologi yang berlaku 
akibat pembentukan bekuan darah pada salur darah arteri mahupun vena. 
Gangguan pada pengaliran darah ini membawa kepada meningkatnya aktiviti 
platelet iaitu pengaktifan, pembebasan granul, aggregasi dan aktiviti lain yang 
berlebihan. Oleh itu, pencarian satu agen yang efektif untuk mengatasi masalah ini 
adalah amat diperlukan. Untuk memenuhi keperluan ini, projek penyelidikan ini 
dijalankan untuk mengkaji kesan kulat merah atau nama saintifiknya Ganoderma 
Jucidum ke atas parameter darah terutamanya mean platelet volume (MPV). Untuk 
tujuan ini, dua jenis ekstrak dihasilkan daripada serbuk komersial Ganoderma 
lucidum iaitu ekstrak air dan ekstrak etanol. Ekstrak- ekstrak ini telah dikaji ke atas 
sampel darah secara in vitro dengan menggunakan kepekatan yang berbeza. 
Setelah ekstrak tersebut dicampurkan ke dalam darah, parameter hematologi 
diukur dengan menggunakan penganalisa hematologi (Abbott Celldyn 4000) untuk 
selang masa yang tertentu iaitu parameter hematologi telah diukur setiap 30 minit 
selama 2 jam. Keputusan daripada kajian ini menunjukkan kesan yang nyata ke 
atas MPV untuk perbezaan di antara selang masa tertentu dan kesan yang terlalu 
kecil atau tiada kesan yang nyata untuk perbezaan antara kepekatan dan jenis 
ekstrak yang digunakan. Keputusan yang diperolehi daripada kajian ini mungkin 
dapat membantu kajian in vivo atau kajian lanjutan selepas ini. Kajian jangka 
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panjang dengan menggunakan kaedah yang lebih specifik juga perlu dilakukan 
untuk mengkaji kesan kulat ini ke atas sel darah terutamanya ke atas aggregasi 
platelet dan potensinya dalam mencegah trombosis. 
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1. INTRODUCTION 
During last decades, several major advancements in medicine came from 
lower organisms such as fungi and yeasts. Antibiotics such as penicillin and 
tetracycline were derived from moulds are a major example of this advancement. 
In another development, cyclosporin derived from a species of yeast was used as 
a powerful immunosuppressive drug. Therefore it would be by no means 
unprecedented if Ganoderma mushroom, which has been claimed to have a lot of 
medicinal properties, will one day be used routinely in medical practice. 
In Asia, mushrooms have been regarded as potent medicine for thousands 
of years. It also has a long history of its use in traditional Chinese medicine 
(Lu et a/, 2004). There are various Ganoderma species like Ganoderma /ucidum, 
Ganoderma app/anatum, Ganoderma tsugae, Ganoderma sinense, Ganoderma 
oregonens and others. In this study, commercially available product of red 
Ganoderma /ucidum was used to study its effect on the hematological parameters 
particularly on mean platelet volume (MPV). 
Ganoderma /ucidum is one of the treasures of Chinese medicine. For 
thousands of years, Ganoderma lucidum, a kind of medicinal fungi, has been 
highly regarded by the Chinese as the "Miraculous King of Herbs." {Mizuno, 1996). 
In the oldest chinese medical directory, "Shen Nang's Materia medica" and "Pen-
ts'ao Kanmu" (Compendium of Materia Medica) written respectively in the Han and 
Ming dynasties, both rated Ganoderma lucidum as a superior and the best among 
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all other Chinese herbs. This is because it has valuable properties of an 
adaptogen, which means that it is non-toxic, non-specific and has a normalizing 
effect on the body (Concord International Trading Pty Ltd). 
Ganoderma lucidum is a rare mushroom and it is extremely hard to 
cultivate. In nature, it grows in densely wooded mountain of high humidity and dim 
lighting. The spores of Ganoderma lucidum have tough outer husks that 
germination is almost impossible and these accounts for its rarity (Matsumoto, 
1979). In the past Ganoderma lucidum grow only in small quantities wildly and 
relatively rare, so that it was very expensive. However, in 1972, researchers at 
Kyoto University in Japan had successfully cultivated Ganoderma lucidum in the 
laboratory (Willard, 1991 ). Now, there are many companies actively cultivate this 
mushroom for commercial purposes and this make it available to almost everyone 
who wish to consume or use it. 
Its effectiveness as a highly potent medicine have been demonstrated by 
over 30 years of modern scientific research in Japan, Taiwan, China, U.S.A. , 
Canada, and Poland. Backed by 5,000 years of accumulated experience, 
Ganoderma lucidum can safely claim to be totally free from side effects (Kim et a!, 
1986). However, the wide range of potential health benefits that can be derived 
from Ganoderma lucidum is enormous and unmatched. 
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Kingdom Fungi 
Phylum Basidiomycota 
I Class Hymenomycetes 
I Order Aphyllophorales 
I Family Ganodermatacea 
I Genus Ganoderma 
I Species I Ganoderma lucidum 
Common Names 
China 
... 
.... Lingzhi 
Japan 
... Reishi, manentake r 
Korea 
_ ... 
r Youngchi 
Malaysia .. Kulat Merah ... 
Figure 1: Taxonomy of Ganoderma lucidum 
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2. REVIEW OF LITERATURE 
2.1 MORPHOLOGY 
Ganoderma /ucidum is the scientific name for this red mushroom. 
Ganoderma lucidum is also known as reishi or mannentake to the Japanese, 
lingzhi to the Chinese, youngchi in Korean and chaga to the Russian. It is a 
basidiomycete, lamellales fungus belonging to the family of polyporaceae. The 
Polyporales form a large group of diverse mushrooms. Most of them are wood 
decomposers whose spores are held in tubes. Many lack fully developed stems, 
and grow shelf-like or crust-like on wood, while some have more or less central 
stems and grow at the bases of trees, and a few appear to actually grow 
terrestrially (Kuo, 2004). 
Figure 2: Ganoderma lucidum 
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The polypores fungi including Ganoderma lucidum can be easily 
distinguished from the other common poroid fungi because of their typically hard 
exterior, usual "non-mushroom" shape, and their usual growth on wood as wood 
decomposers. Some polyporologists place Ganoderma in a separate family, that is 
Ganodermataceae, because it has unusual spore ornamentation that is "double" 
wall properties and this characteristic is highly diagnostic (Kuo, 2004). Ganoderma 
lucidum mushrooms and their mycelium are nature's original recyclers. The fruiting 
bodies of this mushroom are very hard and woody, reddish-orange to black in 
color, have a shiny and varnished appearance on the surface of the cap. The 
mushroom caps are kidney shaped, 3-6 inches in width, with a slender stalk that 
attaches to the indentation in the side of the cap. The under side is creamy colored 
and porous (Maehr, 2004). 
Figure 3: Ganoderma lucidum mushroom 
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Ganoderma lucidum actually possesses many different characteristics and it 
is dependent on the growth location (Jong and Birminghan, 1992). There are six 
different types of Ganoderma lucidum and it is differentiated by its color that is red, 
purple, blue, yellow, black and white. However, these mushrooms actually came 
from one species but grown under different condition (Zhao et a/, 1979). 
Ganoderma /ucidum is now available in capsule or tablet form, which makes it 
possible to avoid the bitter taste and standardize the dosage. The red variety of 
this mushroom is most commonly used and commercially cultivated. Beside that, 
the red type of Ganoderma lucidum is generally regarded as the work-strongest 
(Matsumoto, 1979). 
The fruiting body of red Ganoderma lucidum is extremely bitter and this 
characteristic not found in any other mushroom. The bitter taste of this mushroom 
also was associated with many of its therapeutics characteristics. However, the 
relationship between bitterness and its pharmacological effects is not fully 
understood, the bitterness serves as a marker for pharmacological evaluation and 
classification of Ganoderma species. The bitterness of this mushroom varies in 
degree depending on the place of production, cultivation conditions and its strain 
(Jong and Birmingham, 1992). 
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2.2 MEDICINAL EFFECTS 
Ganoderrna lucidum is rich in mushroom nutriceutical components with 
potential therapeutic values. Chemical investigations on the fruiting bodies, spores 
and mycelia of Ganoderma lucidum reveal that they contain various bioactive 
substances. Active constituents of Ganoderma lucidum including polysaccharides 
that is a bioactive polygycans in Ganoderma lucidum and is found in all parts of the 
mushroom, organic germanium, triterpenoids, adenosine, LZ-8, and an array of 
amino acids besides numerous types of mineral. In addition to all of the ingredients 
in the fruit body, Ganoderrna lucidum mycelium contains higher level of the 
ribonucleic acid (RNA), oleic acid, cyclooctasulfur and also LZ-8 (Mizuno, 1991; 
Yeung eta/, 2004). 
In the first Chinese herbal text, Shennong's Pharmacopeia written about 
2400 years ago, Ganoderma lucidum was classified as a "superior herb" which is 
defined as one that serves to maintain life, promote radiant health and long life 
because of its normalizing action, and to cause no side effects, even when used 
continuously. Beside that, the ancient book said continuous consumption of 
Ganoderma lucidum makes your body light and young, lengthens your life and 
turns you into one like the immortal who never dies. Thus Ganoderrna lucidum was 
traditionally called "the mushroom of immortality." 
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There were a lot of evidences to suggest that Ganoderma lucidum does 
have medicinal potential. The fruiting body of Ganoderma lucidum has been used 
for the prevention and treatment of various diseases in the Orient. It is a well-
known traditional crude drug in the Orient to treat hepatopathy, chronic hepatitis, 
nephritis, gastric ulcer, hypertension, arthritis, neurasthenia, insomnia and 
bronchitis (Kim et at, 1980). In the Orient it was also used as talisman, in order to 
protect humans or homes against bad omen {Matsumoto, 1979). 
As through the review, there were a lot of researches already done to 
demonstrate the medicinal effect of water and ethanol extracts of Ganoderma 
lucidum. However, most of those researches were centered on the ability of 
mushroom compound to enhance the immune system and exert anti-cancer 
actions. In modern clinical trials, the extract of Ganoderma /ucidum show 
therapeutic efficacy in treating cancer and inhibits cell metastasis (Kim et a/, 1980; 
Wang et a/, 1993; Zhang et a/, 2002). 
Besides, the polysaccharide of Ganoderma lucidum seems to have promise 
as a new type of carcinostatic agent, which might be useful in immunotherapy; this 
is because this mushroom can give immunomodulatory effects (Morigiwa et at. 
1986 and Mizuno, 1992). Zhang et a/, 2002 have demonstrated, a bioactive 
fraction isolated from fruiting body of Ganoderrna lucidum stimulated the activation 
and proliferation of mouse spleen B lymphocytes and may be effective in improving 
the immune response in tumor patients. Another medicinal property and potency of 
Ganoderma lucidum that has been proposed and studied was on its hypotensive 
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action. Ganoderma lucidum would limit blood pressure by blocking the renin-
angiotensin system that is responsible for the hypertension and it does occur due 
to the presence ganoderic acid that exerts their hypotensive activities (Morigiwa et 
a/, 1986). 
Various studies were also done to see the effect of this mushroom on 
bronchitis (Dunham, 2000), anti-angiogenic (Cheng eta/, 1986), hepatoprotective 
effect (Hirotani et a/, 1986), anti-histamine release and anti allergies (Kohda et a/, 
1985), blood sugar level reducing properties (Hikino et a/, 1985), lipolysis (Kubo et 
a/, 1980), anti-HIV (Luu, 1992), anti-hyperlipidemic (Liu et a/, 1988), analgesic 
(Kubota et a/, 1982), radiation protective (Chu et a/, 1988) and many others. 
However, the primary objective of this study was to evaluate the effects of 
water and ethanol extracts of Ganodenna lucidum in vitro on blood parameters, 
particularly on platelet aggregation. As in the literature review, many articles have 
been reported that Ganoderma lucidum contains adenosine and this compound is 
responsible for the ability of this mushroom to inhibit platelet aggregation (Shimizu 
eta/, 1985; Wang eta/, 1989). 
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2.3 SIDE EFFECTS 
Ganoderma lucidum is known generally to be safe for long term use. Kim et 
a/, 1986 has reported that the extract of Ganoderma lucidum did not show any 
conceivable toxicity thus it was considered as a very safe mushroom to be 
consumed. However, this mushroom is a blood vessel dilator, which can accelerate 
blood circulation and also has the ability to inhibit platelet aggregation {Shimizu et 
a/, 1985; Wang et a/, 1991). As such, precautions should be taken to stop 
temporarily the usage of Ganoderma lucidum supplement during surgery or with 
severe cuts to avoid excessive bleeding. It is also not recommended for those 
taking anticoagulant medications. Pregnant or lactating women also should consult 
their physician before taking Ganoderma lucidum as a food supplement. 
In general, Ganoderma lucidum is non-toxic, even when used at high 
therapeutic doses. Allergic reactions due to consumption of Ganoderma lucidum 
have not been reported. However, as with many herbal supplements, mild side 
effects may include dizziness, dryness of the mouth, throat and nasal areas, upset 
stomach or loose stools and abdominal upset might occur (Chang, 2004). 
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2.4 OVERVIEW OF HEMOSTASIS 
The ability of the body to control the flow of blood following vascular injury is 
paramount to continued survival. The process of blood clotting and the subsequent 
dissolution of the clot, following repair of the injured tissue, is termed hemostasis. 
Hemostasis composed of four major events that occur in a set order following the 
loss of vascular integrity. 
The initial phase of the process is vascular constriction. This limits the flow 
of blood to the area of injury. Next, platelets become activated by thrombin and 
aggregate at the site of injury, forming a temporary, loose platelet plug. The protein 
fibrinogen is primarily responsible for stimulating platelet clumping. Platelets clump 
by binding to collagen that becomes exposed following rupture of the endothelial 
lining of vessels. Upon activation, platelets release adenosine-5'-diphosphate, 
thromboxane A2 (TXA2), serotonin, phospholipids, lipoproteins, and other proteins 
important for the coagulation cascade. In addition to induced secretion, activated 
platelets change their shape to accommodate the formation of the plug. To ensure 
stability of the initially loose platelet plug, a fibrin clot forms and entraps the plug. 
Finally, the clot must be dissolved in order for normal blood flow to resume 
following tissue repair. The dissolution of the clot occurs through the action of 
plasmin (Guyton and Hall, 1996} 
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In order for hemostasis to occur, platelets must adhere to exposed collagen; 
release the contents of their granules and aggregate. The initial activation of 
platelets is induced by thrombin binding to specific receptors on the surface of 
platelets, thereby initiating a signal transduction cascade. The thrombin receptor is 
coupled to a G-protein that, in tum, activates phospholipase C-y (PLC-y). PLC-y 
hydrolyzes phosphatidylinositol-4, 5-bisphosphate (PIP2) leading to the formation of 
inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 induces the release of 
intracellular Ca2+ stores, and DAG activates protein kinase C (PKC). The collagen 
to which platelets adhere as well as the release of intracellular Ca2+ leads to the 
activation of phospholipase A2 (PLA2), which then hydrolyzes membrane 
phospholipids, leading to liberation of arachidonic acid. The arachidonic acid 
release leads to an increase in the production and subsequent release of 
thromboxane A2 (TXA2). This activated protein induces the release of platelet 
granule contents; one of which is adenosine diphosphate (ADP). ADP further 
stimulates platelets increasing the overall activation cascade; it also modifies the 
platelet membrane in such a way as to allow fibrinogen to adhere to two platelet 
surface glycoproteins, GPIIb and GPIIIa, resulting in fibrinogen-induced platelet 
aggregation {Pierce et a/, 1999). 
2.5 ANTITHROMBOTIC AGENT 
Thrombotic events in high-risk patients for cardiovascular complications and 
stroke may be a consequence of increased platelet activation. Therefore, inhibition 
of platelet reactivity is important for prophylaxis of thromboembolic events. Aspirin 
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is the most commonly used antithrombotic agent in the prevention of vascular 
ischemic events (Halushka et a/, 1995). This is because low-dose of aspirin as 
currently used blocks platelet production of prothrombotic thromboxane A2 and 
allows endothelial synthesis of antithrombotic prostacyclin. By virtue of inhibiting 
the activity of cyclooxygenase, aspirin reduces the production of thromboxane A2. 
Aspirin also reduces endothelial cell production of prostacyclin (PGI2), an 
inhibitor of platelet aggregation and a vasodilator. Localized to the site of 
coagulation is a balance between the levels of platelet-derived thromboxane A2 
(TXA2) and endothelial cell derived PGI2. This allows for platelet aggregation and 
clot formation but preventing excessive accumulation of the clot, thus maintaining 
blood flow around the site of the clot. Endothelial cells regenerate active 
cyclooxygenase faster than platelets because mature platelets cannot synthesize 
the enzyme, requiring new platelets to enter the circulation. Therefore, PG12 
synthesis is greater than that of TXA2. The net effect of aspirin is more in favor of 
endothelial cell-mediated inhibition of the coagulation cascade. This reflects the 
cardiovascular benefits to low dose administration of aspirin. However, there is a 
large group of patients with thrombotic disorders who do not respond to aspirin 
treatment (Altman eta/, 2004). 
Aspirin has reduced the incidence of vascular events by only 25o/o for a 
broad range of patients at risk for occlusive vascular diseases (Hirsh et a/, 1995; 
Patrone, 1994). Prolonged usage of aspirin and ticlopidide as anti-thrombotic agent 
is also limited because of several adverse effects. Adverse reactions like gastric 
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bleeding, allergy like asthma, angioneurotic edema, urticaria, rashes, rhinorhoea 
and it also may aggravate chronic urticaria and other symptom may occur (Hillman 
and Ault, 1998) 
2.6 PLATELET AGGREGATION INHIBITORY EFFECT 
Ganoderrna lucidum has been traditionally used for treatment of 
atherosclerosis, heart problems, high blood pressure, insomnia, blood clots and 
others. Some active compounds have been isolated from this mushroom as 
platelet aggregation inhibitor. It has recently been found that the water-soluble 
fraction of Ganoderrna Jucidum was able to suppress platelet aggregation with an 
inhibitory substance having been identified as adenosine. Its structure has been 
identified as both epimers of 5'-deoxy-S'methylsulphinyl adenosine (Shimizu et a/, 
1985). Adenosine seems to have a stronger effect on platelet aggregation induced 
by thrombin than on that induced by adenosine diphosphate (ADP) (Kasahara et 
a/, 1987). These characteristics are in good agreement with what they have 
observed with the inhibitor obtained from Ganoderma lucidum. The content of 
adenosine in this fungus was found to be at least 40mg/IOO g of dried preparation. 
However, the adenosine content of different kinds of Ganoderma lucidum is 
different (Shiao et a/, 1994 ). Experimental and clinical studies on inhibitory effect of 
ganoderma lucidum on platelet aggregation was also done previously by Toa and 
Feng (1990) from Tongji Medical University of Wuhan and the results suggested 
that this mushroom may have effective inhibitory agent of platelet aggregation. 
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In another study, Chen et a/ (2000} have found that Ganodermic acid S 
(GAS}, isolated from Ganoderrna lucidum, also was shown to have an inhibitory 
effect on platelet responses to various aggregating agonist such as collagen. 
Ganoderic acid is one of the most important components of this mushroom. These 
specific triterpenoids also helps to reduce blood platelets from sticking together 
and this effect is important in lowering the risk for coronary artery disease. GAS is 
an anionic amphiphile and it is highly soluble in platelet plasma membrane. Wang 
et a/ have found that GAS isolated from cultured mycelium of this mushroom could 
be inserted into the membrane of platelets. The morphologically altered membrane 
will occur and can contribute to inhibition of platelet aggregation (Wang et a/, 
1989). 
This effect would be very significant since inhibition of platelet aggregation 
reduces the incidence of blood clots and strokes. However these findings are also 
significant in another ways. If Ganoderrna lucidum does inhibit platelet aggregation 
patients with clotting disorders such as hemophilia or who are on anticoagulants 
therapy should be strongly advised against using Ganoderma lucidum as a 
complementary medicine. Long-term prospective studies are required to assess 
the effect of Ganoderrna lucidum on inhibition of platelet aggregation. One of the 
possible uses of this mushroom is for prophylaxis of arterial thrombosis. 
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3. OBJECTIVES 
The main objective of this study is to verify the effect of Ganoderma lucidum or red 
mushroom on blood parameters especially on inhibition of platelet aggregation. 
-To investigate the effect and permeability of Ganoderma lucidum 
extracts on blood by focusing on hematological parameters especially 
on mean platelet volume (MPV). 
-To compare the effect of water and ethanol extract of 
Ganoderma lucidum on mean platelet volume (MPV) 
-To observe the effect of extracts of Ganoderma lucidum in 
different concentration on MPVat different time intervals. 
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4. MATERIALS AND METHODS 
Below is a list of the equipments and materials that were used during the process 
of conducting my research. These equipments were obtained from the Laboratory 
Facility Unit {UKM- Unit Kemudahan Makmal) of Pusat Pengajian Sains Kesihatan 
(PPSK), Health Campus, Universiti Sains Malaysia (USM). 
4.1 EQUIPMENTS 
1. Electronic balance (Sartorius, BP221 S) 
2. Refrigerator (National, NR-B53FE) 
3. Freeze dry (ilshin Lab Co. Ltd) 
4. Hematology analyzer (Abbott CeiiDyn 4000) 
5. Sonicator (Sonicor, SC-221) 
6. Rotary evaporator (Heildoph Instrument, LABOROTA 4000) 
7. Centrifuge (Hettich Zentrifugen, UNIVERSAL 32R) 
8. Freezer (Fiocchetti Frigoriferi Scientifici) 
9. pH Meter (HANNA Instruments) 
10. Hot air oven (BINDER, 80115) 
4.2 MATERIALS 
Distilled water, ethanol (98 o/o), beaker (250 ml, 500 ml), aluminium foil, glass rod, 
spatula, graduated cylinder (100 ml), filter paper, funnel, universal bottle and 
commercial product of Ganoderma lucidum. 
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4.2.1 Ganoderma lucidum 
Dried powder in capsule from both stages of mushroom, the mushroom 
(fruiting stage) and the mycelium (vegetative stage) of Ganoderma lucidum were 
available commercially as food supplementary products. In this research project 
the mushroom crude (fruiting stage) of a particular brand of commercially available 
Ganoderma lucidum (Gano Excel Enterprise Sdn. Bhd) was selected for the study. 
4.3 EXTRACTION PROCESS 
Ganoderma lucidium comprises of over 200 active compounds (Bidleman, 
2004). In order to isolate these compounds two types of extractions were done 
which were water extract and ethanol extract. In this study, sonicator was used to 
mix and to facilitate in dissolving the crude of Ganoderma lucidum in water and 
ethanol solvent. This step was critical as to ensure that those very small particles 
will be fully dissolved in the mixture. The break down and mixing process were 
done by means of ultrasonic at a very high frequency or intensity. High intensity 
ultrasonic generation is sufficiently powerful to achieve useful liquid processing in a 
wide variety of applications including to increase the solubility of the compounds. 
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4.3.1. Water Extraction 
A water-soluble extract of Ganoderma lucidum was prepared as follows, 
about 1 0 gram of the fine particles of this mushroom from the capsule were 
accurately weighed out and placed in a beaker and then mixed with 100 ml of 
water. The beaker was covered with aluminium foil and the mixtures were placed in 
the sonicator for 1 0 minutes. After that, the mixtures were spun in centrifuge at 600 
rpm for 1 0 minutes and the supernatant was obtained as water-based extraction 
solution. The undissolved particles were separated by filtration and these steps 
were repeated until 50 gram of Ganoderma lucidum powder was used. The 
separated filtrate and sediment were placed in a refrigerator to freeze them, before 
subjected to freeze drying in a vacuum concentrator. 
4.3.2 Ethanol Extraction 
For ethanol extraction, about 5 gram of the fine particles from the freeze 
dried sediment were accurately weighed out and placed in a beaker and then 
mixed with 1 00 ml of ethanol. The beaker was covered with aluminium foil and the 
mixtures were placed in the sonicator for 10 minutes. After that, the mixtures were 
spun in centrifuge at 600rpm for 1 0 minutes and the supernatant was obtained as 
ethanol-based extraction solution. The undissolved particles were removed by 
filtration and the procedures were repeated until 45 gram of Ganoderrna lucidum 
powder was used. The sediment was then discarded. The filtrate was combined, 
and then rotaevaporated using rotary evaporator at 40°C until it concentrated to 
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1/10 of the original volume. Finally, concentrated ethanol extract was allowed to 
dry in hot air oven at 40°C until it was fully dried to obtain the ethanol extract of 
Ganoderma lucidum. 
4.3.3 Principle of Separation Technique 
Centrifugation was a process used to separate or concentrate materials 
suspended in a liquid medium. The theoretical basis of this technique was the 
effect of gravity on particles (including macromolecules) in suspension. Two 
particles of different masses settled in a tube at different rates in response to 
gravity. Particles experiencing a greater centrifugal force had faster sedimentation 
rates and thus were preferentially pulled toward the bottom of the centrifuge tube. 
The centrifugal force generated was proportional to the rotation rate (rpm) of the 
rotor and the distance between the rotor center and the centrifuge tube. 
4.3.4 Freeze Drying 
Freeze-drying was the process whereby water was removed from a material 
under freezing temperatures and a high vacuum. During freeze drying, water was 
transformed directly to gas phase from solid phase, which was ice, without going 
through liquid phase. This process of going directly from a solid to a gas is called 
sublimation. The process required a large amount of energy to obtain the very cold 
temperatures and high vacuum environment needed for this process. 
20 
Freeze drying was a very long process, often taking days or even weeks, 
depending upon the initial concentration of solids of the material to be dried. In this 
study, the samples were placed in an appropriate container for the freeze drying 
process. The operating temperature and pressure were set at 55°F and 200atm 
respectively. In this study the freeze-drying process took about 4 days to complete. 
Powdered extract was obtained from this process and stored in the refrigerator 
before being used in the dosage preparation. 
4.4 PREPARATION OF PHOSPHATE BUFFERED SALINE (PBS) 
SOLUTION A: 0.1M KH2P04 
13.6g of KH2P04 was dissolved in approximately 600ml of distilled water and 
made up to 1 liter with distilled water 
SOLUTION 8: 0.1 M Na2PO! 
14.2g Of Na2P04 was dissolved in approximately 600ml of distilled water and made 
up to 1 liter with distilled water 
Solution A and B were stored at 4°C 
Preparation of pH 7.3 Buffered Saline 
100 ml of a mixture of 23.6 ml of solution A and 76.4 ml of solution B were 
added to every 900 ml of unbuffered saline (0.90%w/v). Following that, the pH of 
the solution was checked using pH meter. Adjustments were made to obtain a 
correct pH using 0.1 M HCI or 0.1 M NaOH (Green eta/, 1987). 
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4.5 DOSE PREPARATION 
4.5.1 Materials 
Ganoderma /ucidum extract powders, phosphate buffer saline (PBS), dimethyl 
sulphoxime (DMSO), electronic balance (Sartorius BP221S), spatula, glass rod, 
EDTA tube (5 ml), plain tube, blood specimen, beaker (50 ml), syringe and needle 
(10 ml), gauze, pipette 1000JJ.I, 20JJ.I (Gilson Pipetman), blue and yellow tips. 
4.5.2 Dosage Preparation 
In this preliminary study, dosages were chosen based on recommendation 
by the manufacturer Gano Excel Enterprise Sdn. Bhd., the company that 
commercially Ganoderma lucidum crude for this study were obtained. Based on 
the instruction recommended by the manufacturer, the consumers have to take two 
capsules per day of this mushroom food supplement for general health 
maintenance. One capsule contains about 300 mg of dried powder of Ganoderma 
lucidum. Therefore, two capsules of Ganoderma lucidum contained about 600 mg 
of crude mushroom powder. It was assumed that normal adults have total blood 
volume of approximately 5 liters in their body. 
Based on the above assumptions, the following calculations were performed: 
5000 ml = 600 mg (daily) 
So 1 ml = 600mg = 0.12 mg/ml blood 
5000 ml 
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Three different doses were used in this study; 0.12 mg/ml, 0.012 mg/ml and 
0.0012 mg/ml. Two types of extracts were prepared and used in this study. They 
were water and ethanol extract of Ganoderma lucidum. 
Crude of Ganoderma lucidum 
I 
Water extract of Ethanol extract of 
Ganoderma lucidum Ganoderma lucidum 
I 
~, ~, ~ 
0.12mg/ml 0.012mg/ml I 0.0012mg/ml 
Figure 4: Dosage prepared from water and ethanol extract of Ganoderma lucidum 
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4.5.3 0.12mg/ml of water and ethanol extract 
The dose 0.12 mg/ml is equivalent to the concentration of 12 mg per one 
milliliter of PBS. In the dosage preparation, about 0.12 gram of the freeze-dried 
powder of Ganoderrna lucidum were accurately weighed out and placed into a 
1 Oml volumetric flask and dissolved with 10 ml of PBS. The solution was mixed 
until all of the extract was completely dissolved in the PBS. Then, the mixture was 
transferred into universal bottle. These same steps were repeated for preparation 
of 0.12 mg/ml of ethanol extract. 
4.5.4 0.012mg/ml of water and ethanol extract 
The dose 0.012 mg/ml is equivalent to the concentration of 1.2 mg per one 
milliliter of PBS. In the dosage preparation, about 0.012 gram of the freeze-dried 
powder of Ganoderrna lucidum was accurately weighed out and placed into a 1Om I 
volumetric flask and dissolved with 1 0 ml of PBS. The solution was mixed until all 
of the extract was completely dissolved in the PBS. Then, the mixture was 
transferred into universal bottle. These same steps were repeated for preparation 
of 0.012 mg/ml of ethanol extract. 
4.5.5 0.0012mg/ml of water and ethanol extract 
The dose 0.0012 mg/ml is equivalent to the concentration of 0.12mg per one 
milliliter of PBS. In the dosage preparation, about 0.0012 gram of the freeze-dried 
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